Novartis: Switching to Gilenya from IFN improves LT outcomes

BUY, Fair Value CHF77 (+15%)

News published on June Monday 10, 2013
Share on

The Essentials

Everything you need to know about investment banking dedicated to growth
Stay Informed
Get our news
Join our Team
Bryan, Garnier & Co is always looking for talent in all our divisions, at all levels
Explore our opportunities